Frank Malinoski

Dr. Malinoski brings over 30 years of executive experience in the biotech and pharmaceutical industries to Affinivax, working on numerous vaccines and immunotherapy products. Dr. Malinoski has an extensive background in the fields of vaccines, immunology, oncology, infectious disease and other key therapeutic areas. He has held senior positions at Liquidia, Wyeth, MedImmune, and Nabi, and held consulting positions at several other biopharmaceutical companies. Dr. Malinoski’s experience includes direct responsibility for clinical development planning, execution, and regulatory interactions of vaccines from Phase I through IV, including the licensure of Prevnar®, Meningitec®, and several combination vaccines. Dr. Malinoski began his career a Clinical Investigator and Chief of Viral Biology at the US Army Medical Research Institute of Infectious Diseases. He received his B.A. from Colby College, his Ph.D. in microbiology from Rutgers University, and his M.D. from Albany Medical College.